LAUNXP Biomedical Co., Ltd
LAUNXP Biomedical Co., Ltd engages in the research and development of drugs for cancer patients. It develops various drugs, which are in preclinical stage, including LXP5948 for non-small cell lung cancer and Alzheimer's disease; LXP5268 for triple negative breast cancer; LXP5101 for pancreatic cancer; LXP1788 for gastrointestinal cancer; and Virus-like particles for cancer and genetic defect tre… Read more
LAUNXP Biomedical Co., Ltd (6876) - Net Assets
Latest net assets as of June 2025: NT$285.37 Million TWD
Based on the latest financial reports, LAUNXP Biomedical Co., Ltd (6876) has net assets worth NT$285.37 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$568.23 Million) and total liabilities (NT$282.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$285.37 Million |
| % of Total Assets | 50.22% |
| Annual Growth Rate | 18.61% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 367.11 |
LAUNXP Biomedical Co., Ltd - Net Assets Trend (2021–2024)
This chart illustrates how LAUNXP Biomedical Co., Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LAUNXP Biomedical Co., Ltd (2021–2024)
The table below shows the annual net assets of LAUNXP Biomedical Co., Ltd from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$108.86 Million | -40.61% |
| 2023-12-31 | NT$183.30 Million | +725.17% |
| 2022-12-31 | NT$22.21 Million | -65.95% |
| 2021-12-31 | NT$65.23 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to LAUNXP Biomedical Co., Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20715600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$439.10 Million | 403.34% |
| Total Equity | NT$108.86 Million | 100.00% |
LAUNXP Biomedical Co., Ltd Competitors by Market Cap
The table below lists competitors of LAUNXP Biomedical Co., Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
COMPAGNIE DES VILLAGES DE L
SEM:COVI
|
$6.19K |
|
Faisal Islamic Bank of Egypt - In EGP
EGX:FAIT
|
$6.19K |
|
Danang Education Investment And Development JSC
VN:DAD
|
$6.19K |
|
Lee Hedges PLC
CM:SHAWN0000
|
$6.20K |
|
NORD3F
SA:NORD3F
|
$6.17K |
|
Scores Hldg Co Inc
PINK:SCRH
|
$6.17K |
|
Image Power S.A.
WAR:IPW
|
$6.17K |
|
ABAS Protect AB
ST:ABAS
|
$6.17K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LAUNXP Biomedical Co., Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 183,296,000 to 108,865,000, a change of -74,431,000 (-40.6%).
- Net loss of 82,595,000 reduced equity.
- New share issuances of 3,458,000 increased equity.
- Other factors increased equity by 4,706,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-82.59 Million | -75.87% |
| Share Issuances | NT$3.46 Million | +3.18% |
| Other Changes | NT$4.71 Million | +4.32% |
| Total Change | NT$- | -40.61% |
Book Value vs Market Value Analysis
This analysis compares LAUNXP Biomedical Co., Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.75x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 11.18x to 6.75x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | NT$2.03 | NT$22.65 | x |
| 2022-12-31 | NT$0.69 | NT$22.65 | x |
| 2023-12-31 | NT$5.69 | NT$22.65 | x |
| 2024-12-31 | NT$3.36 | NT$22.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LAUNXP Biomedical Co., Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -75.87%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3325.08%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.14x
- Recent ROE (-75.87%) is above the historical average (-92.41%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -53.27% | 0.00% | 0.00x | 1.13x | NT$-41.27 Million |
| 2022 | -196.34% | 0.00% | 0.00x | 1.46x | NT$-45.83 Million |
| 2023 | -44.16% | -735900.00% | 0.00x | 1.13x | NT$-99.28 Million |
| 2024 | -75.87% | -3325.08% | 0.02x | 1.14x | NT$-93.48 Million |
Industry Comparison
This section compares LAUNXP Biomedical Co., Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LAUNXP Biomedical Co., Ltd (6876) | NT$285.37 Million | -53.27% | 0.99x | $6.19K |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |